Rheumatoid arthritis is a systemic immune disease that mainly affects the joints. This disease is not completely curable and requires long-term control, and the effectiveness of treatment varies greatly depending on the regimen. Patients with ideal results can have no obvious symptoms despite having the disease for many years, while patients with poor results can develop other systemic diseases such as interstitial lung fibrosis and IgA nephropathy in addition to joint pain and deformation; on the other hand, taking medications may bring about certain liver and kidney damage, and some drugs also bring a heavy financial burden to patients. Therefore, what medications should be used to treat rheumatoid arthritis and when can the medication be reduced are issues of great concern to patients. Rheumatoid arthritis occurs in people aged 30-50 years old, and is characterized by symmetrical pain in the small joints of the limbs (such as finger joints, wrist joints, ankle joints, etc.) that lasts for more than 6 weeks, and daily morning stiffness (inconvenient movement of joints in the morning) for more than one hour. Treatment should be initiated as soon as possible after the diagnosis of rheumatoid arthritis is confirmed. Slow-acting anti-rheumatic drugs such as methotrexate, lorazepam, and leflunomide are the most commonly used drugs to treat rheumatoid arthritis, which can effectively stop the destruction of joint structures by the disease. Therefore, in the early stage of the disease, patients also need to use a combination of non-steroidal anti-inflammatory drugs (such as diclofenac and meloxicam) to relieve joint swelling and pain, help patients move their limbs, and serve as a bridge in the early stage of disease treatment. Professor Zhang pointed out that hormones are not the first choice of drugs for rheumatoid arthritis treatment, but if some patients do not have good results with NSAIDs, they may need to apply hormones to relieve pain symptoms. Patients need regular follow-up after medication, and the safety of medication should be checked one month after the first use of medication, to observe whether methotrexate, leflunomide and other drugs cause white blood cell decline or liver and kidney function damage, patients with mild side effects can use some whitening drugs, liver-protective drugs, while the damage is more serious need to change the drug; after the use of medication every three months need to test the effect of disease treatment, if the test index is not good also need to adjust the drug. For patients who are not well treated with oral medication or who have strong side effects with medication, biologic injection is also a good choice, which works fast but is much more expensive than oral medication. If the examination reveals that the patient’s symptoms are stable and the joint destruction has stopped, the slow-acting anti-rheumatic drugs can be considered to be reduced to a small dose for long-term maintenance treatment. Professor Zhang pointed out that disease reduction and discontinuation is a gradual process, the first thing that needs to be discontinued is the anti-inflammatory drugs, if the patient is not taking NSAIDs or hormones, and there is no joint pain, then it means that the anti-rheumatic drugs have worked and the anti-inflammatory drugs can be discontinued; if the disease is found to be well controlled at the six-month review, the reduction of anti-rheumatic drugs can be put on the treatment agenda. A course of biological agents is six months, and generally speaking, the disease will be significantly improved after one course of treatment and can be discontinued. The reduction of oral drugs should be considered first for drugs with more side effects, or the discontinuation of expensive drugs in the light of the patient’s economic situation; each reduction should be made at an interval of two to three months, during which the changes in rheumatoid factor, blood sedimentation and C-reactive protein should be closely monitored to prevent disease recurrence. This is a slow process, the lower the drug dosage, the slower the reduction. Generally speaking, the drug can be discontinued after 5 years of low-dose control therapy, after which regular follow-up can be done, and patients with good results can stop the drug in 3 years at the shortest.